Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study

Abstract

Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates (PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate- to-severe plaque psoriasis.

Keywords

efficacy / plaque psoriasis / etanercept

References

[1] BeyerV, WolvertonSE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol, 2010, 146(1): 46-54 PMID: 20083692

[2] GriffithsCE, BarkerJN. Pathogenesis and clinical features of psoriasis. Lancet, 2007, 370(9583): 263-271 PMID: 17658397

[3] LiuXX, FengAP, HeYM, et al. . Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis. J Huazhong Univ Sci Technol [Med Sci], 2016, 36(1): 132-136

[4] BusardC, ZweegersJ, LimpensJ, et al. . Combined use of systemic agents for psoriasis: a systematic review. JAMA Dermatol, 2014, 150(11): 1213-1220 PMID: 25188393

[5] GhoreschiK, WeigertC, RockenM. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol, 2007, 25(6): 574-580 PMID: 18021895

[6] LimaXT, OliveiraRT, BragaFG, et al. . Circulating levels of chemokines in psoriasis. Autoimmunity, 2015, 48(1): 57-60 PMID: 25117898

[7] ZhengY, DanilenkoDM, ValdezP, et al. . Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature, 2007, 445(7128): 648-651 PMID: 17187052

[8] ZabaLC, Fuentes-DuculanJ, EungdamrongNJ, et al. . Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol, 2009, 129(1): 79-88 PMID: 18633443

[9] AntigaE, VolpiW, CardilicchiaE, et al. . Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol, 2012, 32(6): 1221-1232 PMID: 22699761

[10] TonelG, ConradC, LaggnerU, et al. . Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol, 2010, 185(10): 5688-5691 PMID: 20956338 PMCID: 3776381

[11] WitteE, KokolakisG, WitteK, et al. . IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol, 2014, 134(11): 2757-2767 PMID: 25046339

[12] SchotteH, SchluterB, WillekeP, et al. . Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology, 2004, 43(8): 960-964 PMID: 15026584

[13] LeonardiCL, PowersJL, MathesonRT, et al. . Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003, 349(21): 2014-2022 PMID: 14627786

[14] PuigL, Camacho MartinezFM, Gimeno CarpioE, et al. . Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology, 2012, 225(3): 220-230 PMID: 23235195

[15] Maria Fernandez-TorresR, ParadelaS, FonsecaE. Long-term efficacy of etanercept for plaque-type psoriasis and estimated cost in daily clinical practice. Value Health, 2015, 18(8): 1158-1161 PMID: 26686803

[16] KivelevitchD, MansouriB, MenterA. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics, 2014, 8: 169-182 PMID: 24790410 PMCID: 4000175

[17] TsaiYC, TsaiTF. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol, 2016, 151(4): 412-431 PMID: 26889727

[18] ChiuHY, WangTS, ChoYT, et al. . Etanercept use for psoriasis in Taiwan: a case series study. Int J Dermatol, 2013, 52(6): 673-680 PMID: 22348620

[19] WuY S, YangCH, HuangYH. Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. Dermatol Sin, 2013, 31: 49-53

[20] FredrikssonT, PetterssonU. Severe psoriasis—oral therapy with a new retinoid. Dermatologica, 1978, 157(4): 238-244 PMID: 357213

[21] CampaM, MansouriB, WarrenR, et al. . A Review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther, 2016, 6(1): 1-12

[22] MorelandLW, SchiffMH, BaumgartnerSW, et al. . Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med, 1999, 130(6): 478-486 PMID: 10075615

[23] NastA, JacobsA, RosumeckS, et al. . Efficacy and safety of systemic long-term treatments for moderateto-severe psoriasis: A systematic review and meta-analysis. J Invest Dermatol, 2015, 135(11): 2641-2648 PMID: 26046458

[24] GriffithsCE, ReichK, LebwohlM, et al. . Comparison of ixekizumab with etanercept or placebo in moderateto-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet, 2015, 386(9993): 541-551 PMID: 26072109

[25] PallerAS, SiegfriedEC, PariserDM, et al. . Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol, 2016, 74(2): 280-287 PMID: 26775775

[26] GottliebAB, LeonardiCL, GoffeBS, et al. . Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol, 2006, 54(3Suppl2): S92-100 PMID: 16488335

[27] PappKA, TyringS, LahfaM, et al. . A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 2005, 152(6): 1304-1312 PMID: 15948997

[28] StrohalR, PuigL, ChouelaE, et al. . The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat, 2013, 24(3): 169-178 PMID: 22251226